INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

INSYS Therapeutics, Inc.

1333 South Spectrum Boulevard
Suite 100
Chandler, AZ 85286
United States
480-500-3127
http://www.insysrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees226

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew G. LongCEO & Director697.1kN/A1965
Mr. Mark E. NanceChief Legal Officer & Gen. Counsel360.16kN/A1968
Ms. Andrece HousleyChief Financial OfficerN/AN/A1968
Dr. Danny L. TuckSr. VP of Quality OperationsN/AN/AN/A
Dr. Venkat Reddy Goskonda Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona. On June 10, 2019, INSYS Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

INSYS Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 10. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.